Novo Nordisk is the company behind the pharmaceutical brands Ozempic and Wegovy and is headquartered in Bagsværd, Denmark. Ozempic is approved for certain adults with type 2 diabetes, while Wegovy is approved in specified markets for chronic weight management; both contain semaglutide.
Novo Nordisk was formed in 1989 through the merger of two Danish companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium. Its history is strongly associated with insulin and other treatments for diabetes and related metabolic conditions.
A common mix-up is treating Ozempic and Wegovy as different active medicines: they are brand names for semaglutide products with different approved uses and dosing presentations. Demand for these medicines significantly increased attention on Novo Nordisk’s sales, capacity, and market value.